Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Evodenoson

Catalog No. T31731Cas No. 844873-47-8
Alias DE-112, DE112, DE 112, ATL-313, ATL313, ATL 313

Evodenoson (ATL313) is a potent and selective adenosine A2a receptor (A2aR) agonist for the treatment of eye diseases, tumors, and immune system disorders, and may be used in studies of open-angle glaucoma and blood tumors.

Evodenoson

Evodenoson

Purity: 100%
Catalog No. T31731Alias DE-112, DE112, DE 112, ATL-313, ATL313, ATL 313Cas No. 844873-47-8
Evodenoson (ATL313) is a potent and selective adenosine A2a receptor (A2aR) agonist for the treatment of eye diseases, tumors, and immune system disorders, and may be used in studies of open-angle glaucoma and blood tumors.
Pack SizePriceAvailabilityQuantity
1 mg$250In Stock
5 mg$630In Stock
10 mg$950In Stock
25 mg$1,828In Stock
50 mg$2,460In Stock
100 mg$3,720In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Evodenoson"

Select Batch
Purity:100%
ee:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Evodenoson (ATL313) is a potent and selective adenosine A2a receptor (A2aR) agonist for the treatment of eye diseases, tumors, and immune system disorders, and may be used in studies of open-angle glaucoma and blood tumors.
In vivo
The rats were divided into 3 groups: Group 1 received a continuous intravenous infusion of saline given 10 min prior to ischemia and throughout reperfusion (n=8); Group 2 received a continuous intravenous infusion of 10 ng/kg/min of ATL 313 given 10 min prior to ischemia and throughout reperfusion (n=8); and group 3 received an intravenous bolus of ATL 313 (900 ng/Kg body weight) given 10 min prior to ischemia, and continuous intravenous infusion of 10 ng/kg/min of ATL 313 started at 20 min after ischemia and throughout reperfusion (n=8). After the euthanasia of the rats, the hearts were harvested for the assessment of the risk zone and zone of necrosis of the left ventricle. Conclusion: A(2A)AR agonist ATL 313 significantly reduced infarct size and improved LV contractility at the end of reperfusion assessed by LV dp/dt at a dose of 900 ng/Kg. The mechanisms for the observed cardioprotection effect of ATL 313 remain to be determined.[2]
AliasDE-112, DE112, DE 112, ATL-313, ATL313, ATL 313
Chemical Properties
Molecular Weight499.52
FormulaC23H29N7O6
Cas No.844873-47-8
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 50 mg/mL (100.1 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.0019 mL10.0096 mL20.0192 mL100.0961 mL
5 mM0.4004 mL2.0019 mL4.0038 mL20.0192 mL
10 mM0.2002 mL1.0010 mL2.0019 mL10.0096 mL
20 mM0.1001 mL0.5005 mL1.0010 mL5.0048 mL
50 mM0.0400 mL0.2002 mL0.4004 mL2.0019 mL
100 mM0.0200 mL0.1001 mL0.2002 mL1.0010 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Evodenoson | purchase Evodenoson | Evodenoson cost | order Evodenoson | Evodenoson chemical structure | Evodenoson in vivo | Evodenoson formula | Evodenoson molecular weight